09:14:36 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandFinland
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Nexstim är verksamma inom medicinteknik. Idag innehas verksamhet främst inom forskning och utveckling av magnetstimulation, en metod som används innan en läkare påbörjar hjärnkirurgi. Tekniken ämnar att kartlägga hjärnan samt uppgifter om hur rehabilitering fortgår för patienter som drabbats av stroke. Bolaget grundades under 2000 och har sitt huvudkontor i Helsingfors.

Kalender

2022-02-28 Bokslutskommuniké 2021
2021-08-13 Kvartalsrapport 2021-Q2
2021-05-17 Split NXTMS 100:1
2021-04-30 Ordinarie utdelning NXTMS 0.00 SEK
2021-04-29 Årsstämma 2021
2021-03-01 Extra Bolagsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-08-14 Kvartalsrapport 2020-Q2
2020-04-01 Ordinarie utdelning NXTMS 0.00 SEK
2020-02-28 Bokslutskommuniké 2019
2019-11-11 Extra Bolagsstämma 2019
2019-08-16 Kvartalsrapport 2019-Q2
2019-03-26 Ordinarie utdelning NXTMS 0.00 SEK
2019-03-25 Årsstämma 2019
2019-03-04 Bokslutskommuniké 2018
2018-11-26 Split NXTMS 30:1
2018-11-21 Extra Bolagsstämma 2018
2018-08-16 Kvartalsrapport 2018-Q2
2018-03-29 Ordinarie utdelning NXTMS 0.00 SEK
2018-03-28 Årsstämma 2018
2018-02-28 Bokslutskommuniké 2017
2017-08-16 Kvartalsrapport 2017-Q2
2017-03-29 Ordinarie utdelning NXTMS 0.00 SEK
2017-03-28 Årsstämma 2017
2017-02-28 Bokslutskommuniké 2016
2017-02-17 Extra Bolagsstämma 2017
2016-08-17 Kvartalsrapport 2016-Q2
2016-04-01 Ordinarie utdelning NXTMS 0.00 SEK
2016-03-31 Årsstämma 2016
2016-02-29 Bokslutskommuniké 2015
2015-12-22 Extra Bolagsstämma 2015
2015-08-20 Kvartalsrapport 2015-Q2
2015-04-01 Ordinarie utdelning NXTMS 0.00 SEK
2015-03-31 Årsstämma 2015
2015-02-26 Bokslutskommuniké 2014
2021-05-07 09:00:00

Press release, Helsinki, 7.5.2021 at 10:00 AM (EEST)

Nexstim Receives a New NBS System Order from a Leading California Based Academic Hospital

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that it has received an NBS system order from a distinguished academic hospital based in Northern California, US.

Nexstim NBS systems use the unique SmartFocus® TMS technology that enables accurate stimulation of the targeted area in the brain. The Nexstim NBS system is the only FDA cleared system based on navigated Transcranial Magnetic Stimulation (nTMS) for non-invasive mapping of the speech and motor cortices of the brain.

Mikko Karvinen, CEO of Nexstim, says: We are happy to announce the sale of this new NBS system to a renowned academic hospital. The NBS business has been a stable source of revenue for us during the COVID-19 pandemic, and we are glad to see an increasing number of patients benefiting from our SmartFocus® TMS technology as the system will be used for motor and speech mapping purposes.”

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information please visit www.nexstim.com